

First DataBank Pricing Confirmation Process

We believe that it is our responsibility as a publisher of pharmaceutical data to ensure that all the drug pricing information we publish is accurate. To fulfill that commitment, we are obliged to confirm on a regular basis that the drug prices we report reflect current manufacturer prices. We have consequently implemented a process of soliciting biannual pricing confirmations from the labelers whose drugs are currently included as active products in our database. This process is a supplement to – and subset of – our broader, ongoing drug product pricing data collection and maintenance.

In accordance with this policy, First DataBank notifies all drug companies that twice a year we forward them a Pricing Update Document that requires their review, completion and signature. We follow this notification with subsequent communications to ensure that labelers understand our need for pricing corroboration and the requirement that they provide it.

In the event that we receive no response to our Pricing Update Document, we make repeated efforts by telephone and email to notify the labeler representatives who have been identified to First DataBank as the appropriate contacts. If this also proves unsuccessful, we will make a final effort by a certified letter to the Chief Executive Office of the non-responding labeler that a continued failure to provide the pricing confirmation will result in the deletion of the company's products from the database. If there is still no response by the labeler, that deletion will occur.

We trust that manufacturers understand the importance of current data to our customers and the corresponding consequences of a failure to provide the pricing verifications as requested.